Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, Status and Forecast 2020-2026

May 2020 | 130 pages | ID: G0299587221AEN
QYResearch

Abstracts

This report focuses on the global Alpha 1 Antitrypsin Deficiency Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alpha 1 Antitrypsin Deficiency Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

• Pfizer
• Baxter
• AstraZeneca
• Grifols
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• Kamada Ltd
• GlaxoSmithKline
• CSL Behring
• Takeda
• LFB Biomedicaments
• Abeona Therapeutics
• Biogen
• Applied Genetic Technologies
• Baxalta
• Arrowhead Research Corporation
• ProBioGen
• Chiesi Pharmaceuticals
• Curaxys
• ProMetic Life Sciences

Market segment by Type, the product can be split into

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy

Market segment by Application, split into

• Hospitals
• Specialty Clinics
• Pharmacies

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Alpha 1 Antitrypsin Deficiency Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Alpha 1 Antitrypsin Deficiency Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Alpha 1 Antitrypsin Deficiency Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Augmentation Therapy
  1.4.3 Bronchodilators
  1.4.4 Corticosteroids
  1.4.5 Oxygen Therapy
1.5 Market by Application
  1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Specialty Clinics
  1.5.4 Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2015-2026)
2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Regions
  2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Alpha 1 Antitrypsin Deficiency Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Alpha 1 Antitrypsin Deficiency Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Market Size
  3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2015-2020)
  3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
  3.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2019
3.3 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.4 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
3.5 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026)

5 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
6.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in North America (2019-2020)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
7.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
8.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in China (2019-2020)
8.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
8.4 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
9.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020)
9.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
9.4 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
10.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
11.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in India (2019-2020)
11.3 India Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
11.4 India Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2015-2020)
12.2 Alpha 1 Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
12.4 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer
  13.1.1 Pfizer Company Details
  13.1.2 Pfizer Business Overview and Its Total Revenue
  13.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020))
  13.1.5 Pfizer Recent Development
13.2 Baxter
  13.2.1 Baxter Company Details
  13.2.2 Baxter Business Overview and Its Total Revenue
  13.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.2.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.2.5 Baxter Recent Development
13.3 AstraZeneca
  13.3.1 AstraZeneca Company Details
  13.3.2 AstraZeneca Business Overview and Its Total Revenue
  13.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.3.5 AstraZeneca Recent Development
13.4 Grifols
  13.4.1 Grifols Company Details
  13.4.2 Grifols Business Overview and Its Total Revenue
  13.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.4.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.4.5 Grifols Recent Development
13.5 Teva Pharmaceutical Industries
  13.5.1 Teva Pharmaceutical Industries Company Details
  13.5.2 Teva Pharmaceutical Industries Business Overview and Its Total Revenue
  13.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.5.5 Teva Pharmaceutical Industries Recent Development
13.6 Boehringer Ingelheim
  13.6.1 Boehringer Ingelheim Company Details
  13.6.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  13.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.6.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.6.5 Boehringer Ingelheim Recent Development
13.7 Kamada Ltd
  13.7.1 Kamada Ltd Company Details
  13.7.2 Kamada Ltd Business Overview and Its Total Revenue
  13.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.7.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.7.5 Kamada Ltd Recent Development
13.8 GlaxoSmithKline
  13.8.1 GlaxoSmithKline Company Details
  13.8.2 GlaxoSmithKline Business Overview and Its Total Revenue
  13.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.8.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.8.5 GlaxoSmithKline Recent Development
13.9 CSL Behring
  13.9.1 CSL Behring Company Details
  13.9.2 CSL Behring Business Overview and Its Total Revenue
  13.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.9.5 CSL Behring Recent Development
13.10 Takeda
  13.10.1 Takeda Company Details
  13.10.2 Takeda Business Overview and Its Total Revenue
  13.10.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
  13.10.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  13.10.5 Takeda Recent Development
13.11 LFB Biomedicaments
  10.11.1 LFB Biomedicaments Company Details
  10.11.2 LFB Biomedicaments Business Overview and Its Total Revenue
  10.11.3 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.11.4 LFB Biomedicaments Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.11.5 LFB Biomedicaments Recent Development
13.12 Abeona Therapeutics
  10.12.1 Abeona Therapeutics Company Details
  10.12.2 Abeona Therapeutics Business Overview and Its Total Revenue
  10.12.3 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.12.4 Abeona Therapeutics Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.12.5 Abeona Therapeutics Recent Development
13.13 Biogen
  10.13.1 Biogen Company Details
  10.13.2 Biogen Business Overview and Its Total Revenue
  10.13.3 Biogen Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.13.4 Biogen Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.13.5 Biogen Recent Development
13.14 Applied Genetic Technologies
  10.14.1 Applied Genetic Technologies Company Details
  10.14.2 Applied Genetic Technologies Business Overview and Its Total Revenue
  10.14.3 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.14.4 Applied Genetic Technologies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.14.5 Applied Genetic Technologies Recent Development
13.15 Baxalta
  10.15.1 Baxalta Company Details
  10.15.2 Baxalta Business Overview and Its Total Revenue
  10.15.3 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.15.4 Baxalta Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.15.5 Baxalta Recent Development
13.16 Arrowhead Research Corporation
  10.16.1 Arrowhead Research Corporation Company Details
  10.16.2 Arrowhead Research Corporation Business Overview and Its Total Revenue
  10.16.3 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.16.4 Arrowhead Research Corporation Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.16.5 Arrowhead Research Corporation Recent Development
13.17 ProBioGen
  10.17.1 ProBioGen Company Details
  10.17.2 ProBioGen Business Overview and Its Total Revenue
  10.17.3 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.17.4 ProBioGen Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.17.5 ProBioGen Recent Development
13.18 Chiesi Pharmaceuticals
  10.18.1 Chiesi Pharmaceuticals Company Details
  10.18.2 Chiesi Pharmaceuticals Business Overview and Its Total Revenue
  10.18.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.18.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.18.5 Chiesi Pharmaceuticals Recent Development
13.19 Curaxys
  10.19.1 Curaxys Company Details
  10.19.2 Curaxys Business Overview and Its Total Revenue
  10.19.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.19.4 Curaxys Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.19.5 Curaxys Recent Development
13.20 ProMetic Life Sciences
  10.20.1 ProMetic Life Sciences Company Details
  10.20.2 ProMetic Life Sciences Business Overview and Its Total Revenue
  10.20.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
  10.20.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
  10.20.5 ProMetic Life Sciences Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Alpha 1 Antitrypsin Deficiency Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
Table 3. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Augmentation Therapy
Table 6. Key Players of Bronchodilators
Table 7. Key Players of Corticosteroids
Table 8. Key Players of Oxygen Therapy
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Regions (2015-2020)
Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Alpha 1 Antitrypsin Deficiency Treatment Market Growth Strategy
Table 19. Main Points Interviewed from Key Alpha 1 Antitrypsin Deficiency Treatment Players
Table 20. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2015-2020) (Million US$)
Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2015-2020)
Table 22. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2019)
Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
Table 26. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2015-2020)
Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026)
Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2015-2020)
Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2026)
Table 34. North America Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 37. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 38. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 40. Europe Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 42. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 44. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 46. China Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 47. China Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 48. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 50. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 52. Japan Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 54. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 56. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 60. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 62. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 64. India Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 65. India Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 66. India Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. India Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 68. India Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. India Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Alpha 1 Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 72. Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 74. Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Product
Table 79. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 80. Pfizer Recent Development
Table 81. Baxter Company Details
Table 82. Baxter Business Overview
Table 83. Baxter Product
Table 84. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 85. Baxter Recent Development
Table 86. AstraZeneca Company Details
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca Product
Table 89. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 90. AstraZeneca Recent Development
Table 91. Grifols Company Details
Table 92. Grifols Business Overview
Table 93. Grifols Product
Table 94. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 95. Grifols Recent Development
Table 96. Teva Pharmaceutical Industries Company Details
Table 97. Teva Pharmaceutical Industries Business Overview
Table 98. Teva Pharmaceutical Industries Product
Table 99. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 100. Teva Pharmaceutical Industries Recent Development
Table 101. Boehringer Ingelheim Company Details
Table 102. Boehringer Ingelheim Business Overview
Table 103. Boehringer Ingelheim Product
Table 104. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 105. Boehringer Ingelheim Recent Development
Table 106. Kamada Ltd Company Details
Table 107. Kamada Ltd Business Overview
Table 108. Kamada Ltd Product
Table 109. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 110. Kamada Ltd Recent Development
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Product
Table 113. GlaxoSmithKline Company Details
Table 114. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 115. GlaxoSmithKline Recent Development
Table 116. CSL Behring Company Details
Table 117. CSL Behring Business Overview
Table 118. CSL Behring Product
Table 119. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 120. CSL Behring Recent Development
Table 121. Takeda Company Details
Table 122. Takeda Business Overview
Table 123. Takeda Product
Table 124. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 125. Takeda Recent Development
Table 126. LFB Biomedicaments Company Details
Table 127. LFB Biomedicaments Business Overview
Table 128. LFB Biomedicaments Product
Table 129. LFB Biomedicaments Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 130. LFB Biomedicaments Recent Development
Table 131. Abeona Therapeutics Company Details
Table 132. Abeona Therapeutics Business Overview
Table 133. Abeona Therapeutics Product
Table 134. Abeona Therapeutics Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 135. Abeona Therapeutics Recent Development
Table 136. Biogen Company Details
Table 137. Biogen Business Overview
Table 138. Biogen Product
Table 139. Biogen Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 140. Biogen Recent Development
Table 141. Applied Genetic Technologies Company Details
Table 142. Applied Genetic Technologies Business Overview
Table 143. Applied Genetic Technologies Product
Table 144. Applied Genetic Technologies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 145. Applied Genetic Technologies Recent Development
Table 146. Baxalta Company Details
Table 147. Baxalta Business Overview
Table 148. Baxalta Product
Table 149. Baxalta Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 150. Baxalta Recent Development
Table 151. Arrowhead Research Corporation Company Details
Table 152. Arrowhead Research Corporation Business Overview
Table 153. Arrowhead Research Corporation Product
Table 154. Arrowhead Research Corporation Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 155. Arrowhead Research Corporation Recent Development
Table 156. ProBioGen Company Details
Table 157. ProBioGen Business Overview
Table 158. ProBioGen Product
Table 159. ProBioGen Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 160. ProBioGen Recent Development
Table 161. Chiesi Pharmaceuticals Company Details
Table 162. Chiesi Pharmaceuticals Business Overview
Table 163. Chiesi Pharmaceuticals Product
Table 164. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 165. Chiesi Pharmaceuticals Recent Development
Table 166. Curaxys Company Details
Table 167. Curaxys Business Overview
Table 168. Curaxys Product
Table 169. Curaxys Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 170. Curaxys Recent Development
Table 171. ProMetic Life Sciences Company Details
Table 172. ProMetic Life Sciences Business Overview
Table 173. ProMetic Life Sciences Product
Table 174. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 175. ProMetic Life Sciences Recent Development
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type: 2020 VS 2026
Figure 2. Augmentation Therapy Features
Figure 3. Bronchodilators Features
Figure 4. Corticosteroids Features
Figure 5. Oxygen Therapy Features
Figure 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Pharmacies Case Studies
Figure 10. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure 11. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2019
Figure 16. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2019
Figure 18. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 27. Baxter Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 29. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 31. Grifols Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 33. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 35. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 37. Kamada Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 39. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 41. CSL Behring Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 43. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 45. LFB Biomedicaments Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. LFB Biomedicaments Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 47. Abeona Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Abeona Therapeutics Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 49. Biogen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Biogen Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 51. Applied Genetic Technologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Applied Genetic Technologies Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 53. Baxalta Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Baxalta Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 55. Arrowhead Research Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Arrowhead Research Corporation Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 57. ProBioGen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. ProBioGen Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 59. Chiesi Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 61. Curaxys Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Curaxys Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 63. ProMetic Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed